Pfizer

Pfizer Net Change in Cash

The Net Change in Cash of Pfizer (PFE) as of Oct 24, 2026 is 99.00 M USD. In the previous year, Net Change in Cash was -1.81 B USD — a change of -105.47% (higher).

Net Change in Cash

99.00 MUSD

YoY

-105.47%

Last updated:

Net Change in Cash of Pfizer is 2025 99.00 M USD. Net Change in Cash of Pfizer was 2024 -1.81 B USD. It decreases by -105.47% higher compared to the previous year.

The Pfizer Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-206.00 M USD
Jan 1, 2019
125.00 M USD
Jan 1, 2020
475.00 M USD
Jan 1, 2021
158.00 M USD
Jan 1, 2022
-1.52 B USD
Jan 1, 2023
2.45 B USD
Jan 1, 2024
-1.81 B USD
Jan 1, 2025
99.00 M USD
The Pfizer Net Change in Cash history
YEARNet Change in CashYoY
99.00 MUSD-105.47%
-1.81 BUSD-173.91%
2.45 BUSD-261.65%
-1.52 BUSD-1,058.86%
158.00 MUSD-66.74%
475.00 MUSD+280.00%
125.00 MUSD-160.68%
-206.00 MUSD-83.56%
-1.25 BUSD+19.79%
-1.05 BUSD-451.01%
298.00 MUSD-74.31%
1.16 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pfizer Stock analysis

What does Pfizer do? Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pfizer stock

Net Change in Cash of Pfizer is 99.00 M USD in 2025.

Net Change in Cash of Pfizer changed from -1.81 B USD to 99.00 M USD, representing a -105.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Pfizer since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Pfizer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Pfizer

All Key Metrics — Pfizer